Patent · US Active

Substituted-indole-compounds as estrogen receptor down-regulators

US10519143B2 · kind B2 · utility

2Cited by

1References

25Claims

0Family size

Assignee

LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD. · CN

Inventors

Jianyu LU · Shanghai, CN
Charles Z. Ding · San Mateo, US
Lihong Hu · Shanghai, CN
Huijun HE · Shanghai, CN
Shuhui CHEN · Shanghai, CN
Jiaqiang Dong · 浮桥镇, CN
Tie-Lin Wang · Shanghai, CN

Key dates

Filing date	Mar 24, 2017
Grant date	Dec 31, 2019
Priority date	—
Expiry date	Mar 24, 2037

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed is a new indole compound, in particular, the compound as shown in formula (I), and a preparation method, pharmaceutical composition and use thereof as an estrogen receptor down-regulator in preparing drugs for treating estrogen receptor-positive breast cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.